Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Conditions
Muscular Dystrophies, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy
Interventions
Retrograde high pressure transvenous perfusion with normal saline
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Glaucoma
Interventions
AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Inglewood, California • Petaluma, California • Poway, California + 15 more
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Conditions
Chronic Kidney Diseases
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danavorexton in Anesthetized Adults

NCT05025397
Conditions
Healthy Volunteers
Interventions
Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Prostate Cancer
Interventions
huJ591, 89Zr-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions
Atorvastatin Calcium
Drug
Lead sponsor
Philip Binkley
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Alcohol Dependence
Interventions
Prazosin Tablet, Placebo Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
SCHIZOPHRENIA 1 (Disorder)
Interventions
Paliperidone Palmitate
Drug
Lead sponsor
Alejandro Alva
Network
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Orange, California • Miami, Florida • Chicago, Illinois
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
18
States / cities
Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more
Conditions
Prostate Cancer
Interventions
Photodynamic Therapy (PDT), Verteporfin Injection
Device · Drug
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Endometriosis, Adenomyosis, Chronic Pelvic Inflammatory Disease
Interventions
Custom-formulated, high-CBD study product, Placebo
Drug
Lead sponsor
Staci Gruber, Ph.D.
Other
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Acute Myeloid Leukaemia
Interventions
S 64315 (also referred as MIK665) and venetoclax
Combination Product
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Conditions
Leukaemia
Interventions
SAR440234
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Persistent Corneal Epithelial Defect
Interventions
KPI-012, KPI-012 Vehicle
Drug
Lead sponsor
Combangio, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Dothan, Alabama • Irvine, California • La Jolla, California + 35 more
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 20 more
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Completed Phase 1 Interventional Results available

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Interventions
IP FT516, Enoblituzumab, IL-2
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
Interventions
Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab, Standard Therapies, Cohort 1
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain Neoplasm, Malignant Glioma
Interventions
Cetuximab, Cetuximab-IRDye 800CW, Tumor resection
Biological · Drug · Procedure
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Palo Alto, California